India Debt Bond Securities SEBI Regulatory Filings — October 26, 2026

Rs 7,816 crore NCD allotment fully subscribed, base Rs 7,000 crore plus Rs 816 crore greenshoe of Rs 3,000 crore available, Series B priced at 8.20% p.a. with Series A at 8.05% and a 2028 put option

Series B issued partly at a Rs 10 premium (issue price Rs 1,00,010 per debenture), indicating demand strong enough to clear above par on a large tranche

Board-authorised issue of up to Rs 2,000 crore of secured NCDs across ZCB G1 and G2 series, with greenshoe headroom of Rs 1,000 crore, pointing to pre-planned funding depth

Rs 5 crore of CARE A1+ commercial paper issued at 8.90% p.a. for roughly four months, the highest short-term rating, confirming market access for a small issuer on a follow-up tranche

Rs 356 crore interest on Rs 5,000 crore LTIP Series II paid on 26.10.2026 on the next business day with no additional interest and no default, a clean servicing record

Standalone revenue rose to Rs 8,344 lakh in Q2 FY27 from Rs 6,838 lakh (about +22% YoY), but net loss widened to Rs 5,903 lakh and H1 loss of Rs 13,550 lakh remains large

Negative standalone equity deepened to Rs (16,285) lakh at 30 September 2026, with cash falling to Rs 185 lakh from Rs 796 lakh at March 2026, a sharp liquidity squeeze

Board approval to raise up to Rs 800 crore of unsecured perpetual debentures reads as a sign of funding stress, with the reported other income of Rs 523 lakh (up from Rs 166 lakh) supporting results rather than operations

Secured structure with first-ranking pari passu charge on hypothecated assets and a 2% p.a. default step-up protects investors versus unsecured alternatives

Standalone equity is negative at Rs (16,285) lakh and the company is now seeking unsecured perpetual debt of up to Rs 800 crore, which ranks behind all senior creditors and carries no maturity

Cash and equivalents collapsed about 77% to Rs 185 lakh from Rs 796 lakh since March 2026 while trade receivables rose to Rs 14,688 lakh, indicating collection slowdown and funding pressure

Revenue growth of about 22% YoY did not translate into profit; net loss widened to Rs 5,903 lakh in Q2 and the reported result leans on other income, raising questions about core operating recovery

Perpetual debentures with no maturity typically carry higher coupons and call-dependent structures, increasing future interest burden on an already loss-making entity

Rs 7,816 crore issued at 8.05–8.20% fixed, with 2028 put option on Series A, creates a concentrated near-term repayment or refinancing event if put is exercised

Full Rs 2,000 crore programme depends on greenshoe subscription beyond base Rs 1,000 crore; partial take-up would leave funding gap and Series-level terms are not disclosed in this filing

Step-up of 2% p.a. only triggers after a three-month delay, meaning a payment default can run quarterly before the coupon uplift applies and cure is at trustee satisfaction

Rs 5 crore issue is small relative to the issuer's funding needs, and a follow-up filing indicates recurring short-tenor reliance on CP rather than term debt

8.20% fixed coupon to October 2031 on a large, fully subscribed AA-range pharma issue offers attractive carry versus sovereign yields for income-oriented debt investors

Investors in Series A at 8.05% gain a par put exercisable 27 March 2028, providing duration protection if rates move higher

Secured first-charge NCDs with a built-in 2% default step-up offer contractual protection and a yield premium for investors seeking secured NBFC exposure

Base of Rs 750 crore (ZCB G1) and Rs 250 crore (G2) with large greenshoe tranches may create allotment opportunities in the early book if demand firms

Four-month CARE A1+ CP at 8.90% discount yield gives treasuries a highest-grade, listed short-tenor parking option on BSE

Confirmed on-time coupon of Rs 356 crore on a Rs 5,000 crore bond series supports holding case for PSU-bank infrastructure paper with an annual coupon cycle and no disruption

Perpetual debenture terms and a Rs 800 crore raise could offer high-coupon instruments to special-situations investors, provided structural subordination and covenant protection are scrutinised

Sun Pharma (Rs 7,816 crore) and Poonawalla (up to Rs 2,000 crore) together account for over Rs 9,800 crore of planned or completed NCD issuance on a single day, showing deep institutional demand for AA-range private placements [implication: primary market is open and pricing is supportive for quality credits]

Poonawalla's secured NCDs with first-charge security contrast with NDTV's proposed unsecured perpetual debentures; the spread between these structures highlights how collateral and maturity terms drive investor protection [implication: weaker issuers are pushed toward riskier, unsecured and perpetual instruments]

A.K. Capital's four-month CARE A1+ CP at 8.90% reflects continued use of CP for working capital by smaller NBFC-type issuers [implication: CP market remains a key funding channel for mid-sized financiers]

Sun Pharma exercised Rs 816 crore of Rs 3,000 crore greenshoe while Poonawalla's greenshoe is sized at Rs 1,000 crore; greenshoe usage is becoming a standard signal of book strength [implication: monitor allotment versus base-issue ratios for pricing sentiment]

Fixed coupons of 8.05–8.20% for Sun Pharma, 8.90% discount for A.K. Capital CP, and perpetual debenture terms for NDTV show wide dispersion driven by rating and balance-sheet strength [implication: spreads between AA-range and weak-credit issuers are likely to widen if stress persists]

Indian Bank's on-time infrastructure bond servicing reinforces the stability of PSU-bank long-term instruments, contrasting with private-sector equity-funded stress elsewhere [implication: PSU infrastructure bonds remain a low-event, carry-oriented holding]

Watch pricing, coupon, call terms and subscription size of up to Rs 800 crore in one or more tranches; ongoing negative equity and Rs 185 lakh cash make execution a key credit event (board approval 26 October 2026, timing of tranches not disclosed)

Track whether revenue growth translates to operating profit and whether cash recovers from Rs 185 lakh; further deterioration would heighten default and rating-downgrade risk (next results expected after 31 December 2026)

Monitor for put-exercise signalling on 27 March 2028 and the refinancing plan for the Rs 2,003 crore Series A if exercised (allotment 26 October 2026, redemption on 27 October 2031)

Watch how much of the Rs 500 crore greenshoe in each series is taken up and the final coupon and tenor disclosed in the Key Information Document (issuance approval 26 October 2026)

Monitor any rating assignment on the secured NCDs and the ZCB G1 structure, as rating changes would directly affect pricing and secondary liquidity (listing on BSE to follow)

Track redemption at Rs 5 crore on 23 February 2027 and any further CP tranches following the 23 October 2026 submission and this 26 October 2026 follow-up

Confirm the next annual coupon on Rs 5,000 crore LTIP Series II expected around 25 October 2027 and monitor for any change in payment frequency or rating (last paid 27 October 2025)